As GE HealthCare Technologies (GEHC) prepares to report quarterly earnings, investors are weighing anticipated revenue growth against recent stock weakness. The spotlight is also on the newly cleared Allia Moveo imaging system, seen as a key growth driver in a competitive medtech landscape.
Medtronic has exercised its option to acquire CathWorks, the developer of the AI-powered FFRangio System, in a deal valued at $585 million. The acquisition, pending regulatory approval, aims to accelerate the transformation of coronary artery disease diagnosis and solidify Medtronic's position in the digital cath lab.
As Tempus AI reaches a key financial milestone, investors are betting its unique combination of diagnostic testing and AI-driven data insights will redefine healthcare profitability.
Following a guidance cut linked to acquisition delays and a softer R&D pipeline, Labcorp Holdings (LH) has embarked on a business restructuring. Despite recent stock momentum, investors are weighing whether the healthcare diagnostics leader remains undervalued or if challenges are already baked into its price.
Johnson & Johnson gains FDA approval for a new frontline multiple myeloma therapy and unveils a pioneering cardiac imaging catheter, reinforcing its strategic focus on high-growth oncology and medical technology segments.
Royal Philips is spearheading a significant European Union-backed consortium, PreciseOnco, aimed at advancing precision oncology through next-generation imaging and minimally invasive therapies. The move comes as the healthcare giant's stock performance draws mixed reviews from the market.
While Danaher met Q4 revenue targets on bioprocessing and diagnostics strength, analyst questions during the earnings call revealed deeper concerns about research funding softness and the sustainability of growth drivers in a challenging macro environment.
As the broader TSX enjoys a robust earnings season, a segment of smaller-cap companies is capturing attention for their high-risk, high-reward potential. We examine three such ventures—spanning cannabis, functional mushrooms, and AI diagnostics—that are on the radar of growth-oriented investors.
Medtronic moves to acquire CathWorks and its AI-powered coronary artery disease diagnostic system, aiming to solidify its position in the catheterization lab and streamline treatment decisions.
Medtronic moves to acquire CathWorks and its non-invasive artery diagnostic system in a deal worth up to $585 million, aiming to strengthen its dominant cardiac portfolio and address a leading cause of heart disease.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Despite a post-earnings slump and near 52-week lows, Abbott Laboratories' resilient medical device unit, strategic expansion in diabetes care, and a landmark acquisition in cancer diagnostics paint a promising long-term picture for this Dividend Aristocrat.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
As Europe's economic recovery finds its footing, investors are looking past the major indices. We analyze three lesser-known companies—from bathroom fixtures to medical tech and energy trading—that combine resilient fundamentals with strategic growth initiatives, offering potential in a complex market landscape.
An analysis using the Discounted Cash Flow model suggests MeVis Medical Solutions AG (ETR:M3V) is trading close to its estimated intrinsic value. While the model provides a framework, experts caution that valuation is an art as much as a science, dependent on key assumptions about growth and risk.
GE HealthCare Technologies' shares have faced recent pressure, lagging behind broader market and industry peers. A deep dive into valuation metrics, including discounted cash flow and P/E analysis, suggests the stock may be significantly undervalued. We examine the numbers and the narratives shaping investor sentiment.
Santec Holdings Corp. (TSE: 6777) experienced a dramatic 46.3% surge in its share price, fueled by a pre-earnings volume spike. As investors pile into the optical technology firm ahead of its May results, analysts debate whether the move reflects robust fundamentals or speculative momentum in a hot sector.
GE HealthCare Technologies reports robust Q4 2025 results, exceeding expectations with 4.8% organic revenue growth. The company enters 2026 with a record $21.8 billion backlog and a strategic focus on its innovation pipeline, including key launches in photon-counting CT and radiopharmaceuticals, while navigating tariff headwinds.
Sony Group Corp. (SONY) was a notable underperformer in Aristotle Capital's Q4 2025 portfolio, dragged down by a significant non-cash impairment charge. While the charge spooked short-term investors, the fund's letter and industry watchers point to the resilience of Sony's core gaming, music, and imaging businesses amidst a booming AI-driven market.
